Overview

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis

Status:
Completed
Trial end date:
2020-01-16
Target enrollment:
Participant gender:
Summary
A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of EDP-305 in subjects with primary biliary cholangitis
Phase:
Phase 2
Details
Lead Sponsor:
Enanta Pharmaceuticals
Collaborators:
Pharmaceutical Research Associates
Triangle Biostatistics